New Delhi, Oct 9 : Drug firm Glenmark Pharmaceuticals on Friday said the addition of antiviral Umifenovir did not demonstrate any significant clinical benefit over Favipiravir alone in moderate COVID-19 patients., New Delhi, Oct 9 : Drug firm Glenmark Pharmaceuticals on Friday said the addition of antiviral Umifenovir did not demonstrate any significant clinical benefit over Favipiravir alone in moderate COVID-19 patients., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way